Pharma & Healthcare
Global Antibody-drug Conjugate for Cancer Market Insights, Forecast to 2030
- Mar 11, 25
- ID: 4315
- Pages: 93
- Figures: 112
- Views: 63
Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.
Market Analysis and Insights: Global Antibody-drug Conjugate for Cancer Market
The global Antibody-drug Conjugate for Cancer market is projected to grow from US$ 895.3 million in 2024 to US$ 1179.4 million by 2030, at a Compound Annual Growth Rate (CAGR) of 4.7% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Antibody-drug Conjugate for Cancer market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Antibody-drug Conjugate for Cancer, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Antibody-drug Conjugate for Cancer, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Antibody-drug Conjugate for Cancer revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Antibody-drug Conjugate for Cancer market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Antibody-drug Conjugate for Cancer revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Gilead Sciences
Roche
Pfizer
Takeda
Seagen
Innate Pharma
AstraZeneca
GSK
Rakuten Medical
Segment by Type
Hematological Malignancies Drugs
Solid Tumor Drugs
Segment by Application
Hospital
Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Antibody-drug Conjugate for Cancer in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody-drug Conjugate for Cancer companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody-drug Conjugate for Cancer revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Market Analysis and Insights: Global Antibody-drug Conjugate for Cancer Market
The global Antibody-drug Conjugate for Cancer market is projected to grow from US$ 895.3 million in 2024 to US$ 1179.4 million by 2030, at a Compound Annual Growth Rate (CAGR) of 4.7% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Antibody-drug Conjugate for Cancer market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Antibody-drug Conjugate for Cancer, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Antibody-drug Conjugate for Cancer, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Antibody-drug Conjugate for Cancer revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Antibody-drug Conjugate for Cancer market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Antibody-drug Conjugate for Cancer revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Gilead Sciences
Roche
Pfizer
Takeda
Seagen
Innate Pharma
AstraZeneca
GSK
Rakuten Medical
Segment by Type
Hematological Malignancies Drugs
Solid Tumor Drugs
Segment by Application
Hospital
Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Antibody-drug Conjugate for Cancer in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody-drug Conjugate for Cancer companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody-drug Conjugate for Cancer revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Hematological Malignancies Drugs
1.2.3 Solid Tumor Drugs
1.3 Market by Application
1.3.1 Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody-drug Conjugate for Cancer Market Perspective (2019-2030)
2.2 Global Antibody-drug Conjugate for Cancer Growth Trends by Region
2.2.1 Antibody-drug Conjugate for Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Antibody-drug Conjugate for Cancer Historic Market Size by Region (2019-2024)
2.2.3 Antibody-drug Conjugate for Cancer Forecasted Market Size by Region (2025-2030)
2.3 Antibody-drug Conjugate for Cancer Market Dynamics
2.3.1 Antibody-drug Conjugate for Cancer Industry Trends
2.3.2 Antibody-drug Conjugate for Cancer Market Drivers
2.3.3 Antibody-drug Conjugate for Cancer Market Challenges
2.3.4 Antibody-drug Conjugate for Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Antibody-drug Conjugate for Cancer by Players
3.1.1 Global Antibody-drug Conjugate for Cancer Revenue by Players (2019-2024)
3.1.2 Global Antibody-drug Conjugate for Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Antibody-drug Conjugate for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Antibody-drug Conjugate for Cancer, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Antibody-drug Conjugate for Cancer Market Concentration Ratio
3.4.1 Global Antibody-drug Conjugate for Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody-drug Conjugate for Cancer Revenue in 2023
3.5 Global Key Players of Antibody-drug Conjugate for Cancer Head office and Area Served
3.6 Global Key Players of Antibody-drug Conjugate for Cancer, Product and Application
3.7 Global Key Players of Antibody-drug Conjugate for Cancer, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody-drug Conjugate for Cancer Breakdown Data by Type
4.1 Global Antibody-drug Conjugate for Cancer Historic Market Size by Type (2019-2024)
4.2 Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Type (2025-2030)
5 Antibody-drug Conjugate for Cancer Breakdown Data by Application
5.1 Global Antibody-drug Conjugate for Cancer Historic Market Size by Application (2019-2024)
5.2 Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Antibody-drug Conjugate for Cancer Market Size (2019-2030)
6.2 North America Antibody-drug Conjugate for Cancer Market Size by Type
6.2.1 North America Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024)
6.2.2 North America Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030)
6.2.3 North America Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
6.3 North America Antibody-drug Conjugate for Cancer Market Size by Application
6.3.1 North America Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024)
6.3.2 North America Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030)
6.3.3 North America Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
6.4 North America Antibody-drug Conjugate for Cancer Market Size by Country
6.4.1 North America Antibody-drug Conjugate for Cancer Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Antibody-drug Conjugate for Cancer Market Size by Country (2019-2024)
6.4.3 North America Antibody-drug Conjugate for Cancer Market Size by Country (2025-2030)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Antibody-drug Conjugate for Cancer Market Size (2019-2030)
7.2 Europe Antibody-drug Conjugate for Cancer Market Size by Type
7.2.1 Europe Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024)
7.2.2 Europe Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030)
7.2.3 Europe Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
7.3 Europe Antibody-drug Conjugate for Cancer Market Size by Application
7.3.1 Europe Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024)
7.3.2 Europe Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030)
7.3.3 Europe Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
7.4 Europe Antibody-drug Conjugate for Cancer Market Size by Country
7.4.1 Europe Antibody-drug Conjugate for Cancer Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Antibody-drug Conjugate for Cancer Market Size by Country (2019-2024)
7.4.3 Europe Antibody-drug Conjugate for Cancer Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Antibody-drug Conjugate for Cancer Market Size (2019-2030)
8.2 China Antibody-drug Conjugate for Cancer Market Size by Type
8.2.1 China Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024)
8.2.2 China Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030)
8.2.3 China Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
8.3 China Antibody-drug Conjugate for Cancer Market Size by Application
8.3.1 China Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024)
8.3.2 China Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030)
8.3.3 China Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Antibody-drug Conjugate for Cancer Market Size (2019-2030)
9.2 Asia Antibody-drug Conjugate for Cancer Market Size by Type
9.2.1 Asia Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024)
9.2.2 Asia Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030)
9.2.3 Asia Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
9.3 Asia Antibody-drug Conjugate for Cancer Market Size by Application
9.3.1 Asia Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024)
9.3.2 Asia Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030)
9.3.3 Asia Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
9.4 Asia Antibody-drug Conjugate for Cancer Market Size by Region
9.4.1 Asia Antibody-drug Conjugate for Cancer Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Antibody-drug Conjugate for Cancer Market Size by Region (2019-2024)
9.4.3 Asia Antibody-drug Conjugate for Cancer Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Type
10.2.1 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Application
10.3.1 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Country
10.4.1 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Gilead Sciences
11.1.1 Gilead Sciences Company Details
11.1.2 Gilead Sciences Business Overview
11.1.3 Gilead Sciences Antibody-drug Conjugate for Cancer Introduction
11.1.4 Gilead Sciences Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.1.5 Gilead Sciences Recent Developments
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Antibody-drug Conjugate for Cancer Introduction
11.2.4 Roche Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.2.5 Roche Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Antibody-drug Conjugate for Cancer Introduction
11.3.4 Pfizer Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.3.5 Pfizer Recent Developments
11.4 Takeda
11.4.1 Takeda Company Details
11.4.2 Takeda Business Overview
11.4.3 Takeda Antibody-drug Conjugate for Cancer Introduction
11.4.4 Takeda Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.4.5 Takeda Recent Developments
11.5 Seagen
11.5.1 Seagen Company Details
11.5.2 Seagen Business Overview
11.5.3 Seagen Antibody-drug Conjugate for Cancer Introduction
11.5.4 Seagen Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.5.5 Seagen Recent Developments
11.6 Innate Pharma
11.6.1 Innate Pharma Company Details
11.6.2 Innate Pharma Business Overview
11.6.3 Innate Pharma Antibody-drug Conjugate for Cancer Introduction
11.6.4 Innate Pharma Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.6.5 Innate Pharma Recent Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Company Details
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Antibody-drug Conjugate for Cancer Introduction
11.7.4 AstraZeneca Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.7.5 AstraZeneca Recent Developments
11.8 GSK
11.8.1 GSK Company Details
11.8.2 GSK Business Overview
11.8.3 GSK Antibody-drug Conjugate for Cancer Introduction
11.8.4 GSK Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.8.5 GSK Recent Developments
11.9 Rakuten Medical
11.9.1 Rakuten Medical Company Details
11.9.2 Rakuten Medical Business Overview
11.9.3 Rakuten Medical Antibody-drug Conjugate for Cancer Introduction
11.9.4 Rakuten Medical Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.9.5 Rakuten Medical Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Hematological Malignancies Drugs
1.2.3 Solid Tumor Drugs
1.3 Market by Application
1.3.1 Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody-drug Conjugate for Cancer Market Perspective (2019-2030)
2.2 Global Antibody-drug Conjugate for Cancer Growth Trends by Region
2.2.1 Antibody-drug Conjugate for Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Antibody-drug Conjugate for Cancer Historic Market Size by Region (2019-2024)
2.2.3 Antibody-drug Conjugate for Cancer Forecasted Market Size by Region (2025-2030)
2.3 Antibody-drug Conjugate for Cancer Market Dynamics
2.3.1 Antibody-drug Conjugate for Cancer Industry Trends
2.3.2 Antibody-drug Conjugate for Cancer Market Drivers
2.3.3 Antibody-drug Conjugate for Cancer Market Challenges
2.3.4 Antibody-drug Conjugate for Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Antibody-drug Conjugate for Cancer by Players
3.1.1 Global Antibody-drug Conjugate for Cancer Revenue by Players (2019-2024)
3.1.2 Global Antibody-drug Conjugate for Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Antibody-drug Conjugate for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Antibody-drug Conjugate for Cancer, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Antibody-drug Conjugate for Cancer Market Concentration Ratio
3.4.1 Global Antibody-drug Conjugate for Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody-drug Conjugate for Cancer Revenue in 2023
3.5 Global Key Players of Antibody-drug Conjugate for Cancer Head office and Area Served
3.6 Global Key Players of Antibody-drug Conjugate for Cancer, Product and Application
3.7 Global Key Players of Antibody-drug Conjugate for Cancer, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody-drug Conjugate for Cancer Breakdown Data by Type
4.1 Global Antibody-drug Conjugate for Cancer Historic Market Size by Type (2019-2024)
4.2 Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Type (2025-2030)
5 Antibody-drug Conjugate for Cancer Breakdown Data by Application
5.1 Global Antibody-drug Conjugate for Cancer Historic Market Size by Application (2019-2024)
5.2 Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Antibody-drug Conjugate for Cancer Market Size (2019-2030)
6.2 North America Antibody-drug Conjugate for Cancer Market Size by Type
6.2.1 North America Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024)
6.2.2 North America Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030)
6.2.3 North America Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
6.3 North America Antibody-drug Conjugate for Cancer Market Size by Application
6.3.1 North America Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024)
6.3.2 North America Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030)
6.3.3 North America Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
6.4 North America Antibody-drug Conjugate for Cancer Market Size by Country
6.4.1 North America Antibody-drug Conjugate for Cancer Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Antibody-drug Conjugate for Cancer Market Size by Country (2019-2024)
6.4.3 North America Antibody-drug Conjugate for Cancer Market Size by Country (2025-2030)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Antibody-drug Conjugate for Cancer Market Size (2019-2030)
7.2 Europe Antibody-drug Conjugate for Cancer Market Size by Type
7.2.1 Europe Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024)
7.2.2 Europe Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030)
7.2.3 Europe Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
7.3 Europe Antibody-drug Conjugate for Cancer Market Size by Application
7.3.1 Europe Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024)
7.3.2 Europe Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030)
7.3.3 Europe Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
7.4 Europe Antibody-drug Conjugate for Cancer Market Size by Country
7.4.1 Europe Antibody-drug Conjugate for Cancer Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Antibody-drug Conjugate for Cancer Market Size by Country (2019-2024)
7.4.3 Europe Antibody-drug Conjugate for Cancer Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Antibody-drug Conjugate for Cancer Market Size (2019-2030)
8.2 China Antibody-drug Conjugate for Cancer Market Size by Type
8.2.1 China Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024)
8.2.2 China Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030)
8.2.3 China Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
8.3 China Antibody-drug Conjugate for Cancer Market Size by Application
8.3.1 China Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024)
8.3.2 China Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030)
8.3.3 China Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Antibody-drug Conjugate for Cancer Market Size (2019-2030)
9.2 Asia Antibody-drug Conjugate for Cancer Market Size by Type
9.2.1 Asia Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024)
9.2.2 Asia Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030)
9.2.3 Asia Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
9.3 Asia Antibody-drug Conjugate for Cancer Market Size by Application
9.3.1 Asia Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024)
9.3.2 Asia Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030)
9.3.3 Asia Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
9.4 Asia Antibody-drug Conjugate for Cancer Market Size by Region
9.4.1 Asia Antibody-drug Conjugate for Cancer Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Antibody-drug Conjugate for Cancer Market Size by Region (2019-2024)
9.4.3 Asia Antibody-drug Conjugate for Cancer Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Type
10.2.1 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Application
10.3.1 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Country
10.4.1 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Gilead Sciences
11.1.1 Gilead Sciences Company Details
11.1.2 Gilead Sciences Business Overview
11.1.3 Gilead Sciences Antibody-drug Conjugate for Cancer Introduction
11.1.4 Gilead Sciences Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.1.5 Gilead Sciences Recent Developments
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Antibody-drug Conjugate for Cancer Introduction
11.2.4 Roche Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.2.5 Roche Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Antibody-drug Conjugate for Cancer Introduction
11.3.4 Pfizer Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.3.5 Pfizer Recent Developments
11.4 Takeda
11.4.1 Takeda Company Details
11.4.2 Takeda Business Overview
11.4.3 Takeda Antibody-drug Conjugate for Cancer Introduction
11.4.4 Takeda Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.4.5 Takeda Recent Developments
11.5 Seagen
11.5.1 Seagen Company Details
11.5.2 Seagen Business Overview
11.5.3 Seagen Antibody-drug Conjugate for Cancer Introduction
11.5.4 Seagen Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.5.5 Seagen Recent Developments
11.6 Innate Pharma
11.6.1 Innate Pharma Company Details
11.6.2 Innate Pharma Business Overview
11.6.3 Innate Pharma Antibody-drug Conjugate for Cancer Introduction
11.6.4 Innate Pharma Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.6.5 Innate Pharma Recent Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Company Details
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Antibody-drug Conjugate for Cancer Introduction
11.7.4 AstraZeneca Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.7.5 AstraZeneca Recent Developments
11.8 GSK
11.8.1 GSK Company Details
11.8.2 GSK Business Overview
11.8.3 GSK Antibody-drug Conjugate for Cancer Introduction
11.8.4 GSK Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.8.5 GSK Recent Developments
11.9 Rakuten Medical
11.9.1 Rakuten Medical Company Details
11.9.2 Rakuten Medical Business Overview
11.9.3 Rakuten Medical Antibody-drug Conjugate for Cancer Introduction
11.9.4 Rakuten Medical Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.9.5 Rakuten Medical Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 2. Key Players of Hematological Malignancies Drugs
Table 3. Key Players of Solid Tumor Drugs
Table 4. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 5. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Antibody-drug Conjugate for Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Antibody-drug Conjugate for Cancer Market Share by Region (2019-2024)
Table 8. Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Antibody-drug Conjugate for Cancer Market Share by Region (2025-2030)
Table 10. Antibody-drug Conjugate for Cancer Market Trends
Table 11. Antibody-drug Conjugate for Cancer Market Drivers
Table 12. Antibody-drug Conjugate for Cancer Market Challenges
Table 13. Antibody-drug Conjugate for Cancer Market Restraints
Table 14. Global Antibody-drug Conjugate for Cancer Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Antibody-drug Conjugate for Cancer Revenue Share by Players (2019-2024)
Table 16. Global Top Antibody-drug Conjugate for Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-drug Conjugate for Cancer as of 2023)
Table 17. Global Antibody-drug Conjugate for Cancer Industry Ranking 2022 VS 2023 VS 2024
Table 18. Global 5 Largest Players Market Share by Antibody-drug Conjugate for Cancer Revenue (CR5 and HHI) & (2019-2024)
Table 19. Global Key Players of Antibody-drug Conjugate for Cancer, Headquarters and Area Served
Table 20. Global Key Players of Antibody-drug Conjugate for Cancer, Product and Application
Table 21. Global Key Players of Antibody-drug Conjugate for Cancer, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Type (2019-2024)
Table 25. Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Type (2025-2030)
Table 27. Global Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Antibody-drug Conjugate for Cancer Revenue Share by Application (2019-2024)
Table 29. Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Antibody-drug Conjugate for Cancer Revenue Share by Application (2025-2030)
Table 31. North America Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 32. North America Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 33. North America Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 34. North America Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 35. North America Antibody-drug Conjugate for Cancer Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Antibody-drug Conjugate for Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Antibody-drug Conjugate for Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 39. Europe Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 40. Europe Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 41. Europe Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 42. Europe Antibody-drug Conjugate for Cancer Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Europe Antibody-drug Conjugate for Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 44. Europe Antibody-drug Conjugate for Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 45. China Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 46. China Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 47. China Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 48. China Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 49. Asia Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 50. Asia Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 51. Asia Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 52. Asia Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 53. Asia Antibody-drug Conjugate for Cancer Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 54. Asia Antibody-drug Conjugate for Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 55. Asia Antibody-drug Conjugate for Cancer Market Size by Region (2025-2030) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 61. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 63. Gilead Sciences Company Details
Table 64. Gilead Sciences Business Overview
Table 65. Gilead Sciences Antibody-drug Conjugate for Cancer Product
Table 66. Gilead Sciences Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 67. Gilead Sciences Recent Developments
Table 68. Roche Company Details
Table 69. Roche Business Overview
Table 70. Roche Antibody-drug Conjugate for Cancer Product
Table 71. Roche Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 72. Roche Recent Developments
Table 73. Pfizer Company Details
Table 74. Pfizer Business Overview
Table 75. Pfizer Antibody-drug Conjugate for Cancer Product
Table 76. Pfizer Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 77. Pfizer Recent Developments
Table 78. Takeda Company Details
Table 79. Takeda Business Overview
Table 80. Takeda Antibody-drug Conjugate for Cancer Product
Table 81. Takeda Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 82. Takeda Recent Developments
Table 83. Seagen Company Details
Table 84. Seagen Business Overview
Table 85. Seagen Antibody-drug Conjugate for Cancer Product
Table 86. Seagen Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 87. Seagen Recent Developments
Table 88. Innate Pharma Company Details
Table 89. Innate Pharma Business Overview
Table 90. Innate Pharma Antibody-drug Conjugate for Cancer Product
Table 91. Innate Pharma Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 92. Innate Pharma Recent Developments
Table 93. AstraZeneca Company Details
Table 94. AstraZeneca Business Overview
Table 95. AstraZeneca Antibody-drug Conjugate for Cancer Product
Table 96. AstraZeneca Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 97. AstraZeneca Recent Developments
Table 98. GSK Company Details
Table 99. GSK Business Overview
Table 100. GSK Antibody-drug Conjugate for Cancer Product
Table 101. GSK Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 102. GSK Recent Developments
Table 103. Rakuten Medical Company Details
Table 104. Rakuten Medical Business Overview
Table 105. Rakuten Medical Antibody-drug Conjugate for Cancer Product
Table 106. Rakuten Medical Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 107. Rakuten Medical Recent Developments
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 2. Global Antibody-drug Conjugate for Cancer Market Share by Type: 2023 VS 2030
Figure 3. Hematological Malignancies Drugs Features
Figure 4. Solid Tumor Drugs Features
Figure 5. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 6. Global Antibody-drug Conjugate for Cancer Market Share by Application: 2023 VS 2030
Figure 7. Hospital Case Studies
Figure 8. Pharmacy Case Studies
Figure 9. Other Case Studies
Figure 10. Antibody-drug Conjugate for Cancer Report Years Considered
Figure 11. Global Antibody-drug Conjugate for Cancer Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Antibody-drug Conjugate for Cancer Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Antibody-drug Conjugate for Cancer Market Share by Region: 2023 VS 2030
Figure 14. Global Antibody-drug Conjugate for Cancer Market Share by Players in 2023
Figure 15. Global Top Antibody-drug Conjugate for Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-drug Conjugate for Cancer as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Antibody-drug Conjugate for Cancer Revenue in 2023
Figure 17. North America Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
Figure 19. North America Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
Figure 20. North America Antibody-drug Conjugate for Cancer Market Share by Country (2019-2030)
Figure 21. United States Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Antibody-drug Conjugate for Cancer Market Size YoY (2019-2030) & (US$ Million)
Figure 24. Europe Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
Figure 25. Europe Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
Figure 26. Europe Antibody-drug Conjugate for Cancer Market Share by Country (2019-2030)
Figure 27. Germany Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. China Antibody-drug Conjugate for Cancer Market Size YoY (2019-2030) & (US$ Million)
Figure 34. China Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
Figure 35. China Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
Figure 36. Asia Antibody-drug Conjugate for Cancer Market Size YoY (2019-2030) & (US$ Million)
Figure 37. Asia Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
Figure 38. Asia Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
Figure 39. Asia Antibody-drug Conjugate for Cancer Market Share by Region (2019-2030)
Figure 40. Japan Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. South Korea Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. China Taiwan Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Southeast Asia Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. India Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Australia Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size YoY (2019-2030) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
Figure 48. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
Figure 49. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Share by Country (2019-2030)
Figure 50. Brazil Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Mexico Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 52. Turkey Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. Israel Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 55. GCC Countries Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 56. Gilead Sciences Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 57. Roche Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 58. Pfizer Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 59. Takeda Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 60. Seagen Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 61. Innate Pharma Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 62. AstraZeneca Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 63. GSK Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 64. Rakuten Medical Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Table 1. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 2. Key Players of Hematological Malignancies Drugs
Table 3. Key Players of Solid Tumor Drugs
Table 4. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 5. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Antibody-drug Conjugate for Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Antibody-drug Conjugate for Cancer Market Share by Region (2019-2024)
Table 8. Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Antibody-drug Conjugate for Cancer Market Share by Region (2025-2030)
Table 10. Antibody-drug Conjugate for Cancer Market Trends
Table 11. Antibody-drug Conjugate for Cancer Market Drivers
Table 12. Antibody-drug Conjugate for Cancer Market Challenges
Table 13. Antibody-drug Conjugate for Cancer Market Restraints
Table 14. Global Antibody-drug Conjugate for Cancer Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Antibody-drug Conjugate for Cancer Revenue Share by Players (2019-2024)
Table 16. Global Top Antibody-drug Conjugate for Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-drug Conjugate for Cancer as of 2023)
Table 17. Global Antibody-drug Conjugate for Cancer Industry Ranking 2022 VS 2023 VS 2024
Table 18. Global 5 Largest Players Market Share by Antibody-drug Conjugate for Cancer Revenue (CR5 and HHI) & (2019-2024)
Table 19. Global Key Players of Antibody-drug Conjugate for Cancer, Headquarters and Area Served
Table 20. Global Key Players of Antibody-drug Conjugate for Cancer, Product and Application
Table 21. Global Key Players of Antibody-drug Conjugate for Cancer, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Type (2019-2024)
Table 25. Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Type (2025-2030)
Table 27. Global Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Antibody-drug Conjugate for Cancer Revenue Share by Application (2019-2024)
Table 29. Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Antibody-drug Conjugate for Cancer Revenue Share by Application (2025-2030)
Table 31. North America Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 32. North America Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 33. North America Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 34. North America Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 35. North America Antibody-drug Conjugate for Cancer Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Antibody-drug Conjugate for Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Antibody-drug Conjugate for Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 39. Europe Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 40. Europe Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 41. Europe Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 42. Europe Antibody-drug Conjugate for Cancer Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Europe Antibody-drug Conjugate for Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 44. Europe Antibody-drug Conjugate for Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 45. China Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 46. China Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 47. China Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 48. China Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 49. Asia Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 50. Asia Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 51. Asia Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 52. Asia Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 53. Asia Antibody-drug Conjugate for Cancer Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 54. Asia Antibody-drug Conjugate for Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 55. Asia Antibody-drug Conjugate for Cancer Market Size by Region (2025-2030) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 61. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 63. Gilead Sciences Company Details
Table 64. Gilead Sciences Business Overview
Table 65. Gilead Sciences Antibody-drug Conjugate for Cancer Product
Table 66. Gilead Sciences Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 67. Gilead Sciences Recent Developments
Table 68. Roche Company Details
Table 69. Roche Business Overview
Table 70. Roche Antibody-drug Conjugate for Cancer Product
Table 71. Roche Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 72. Roche Recent Developments
Table 73. Pfizer Company Details
Table 74. Pfizer Business Overview
Table 75. Pfizer Antibody-drug Conjugate for Cancer Product
Table 76. Pfizer Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 77. Pfizer Recent Developments
Table 78. Takeda Company Details
Table 79. Takeda Business Overview
Table 80. Takeda Antibody-drug Conjugate for Cancer Product
Table 81. Takeda Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 82. Takeda Recent Developments
Table 83. Seagen Company Details
Table 84. Seagen Business Overview
Table 85. Seagen Antibody-drug Conjugate for Cancer Product
Table 86. Seagen Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 87. Seagen Recent Developments
Table 88. Innate Pharma Company Details
Table 89. Innate Pharma Business Overview
Table 90. Innate Pharma Antibody-drug Conjugate for Cancer Product
Table 91. Innate Pharma Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 92. Innate Pharma Recent Developments
Table 93. AstraZeneca Company Details
Table 94. AstraZeneca Business Overview
Table 95. AstraZeneca Antibody-drug Conjugate for Cancer Product
Table 96. AstraZeneca Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 97. AstraZeneca Recent Developments
Table 98. GSK Company Details
Table 99. GSK Business Overview
Table 100. GSK Antibody-drug Conjugate for Cancer Product
Table 101. GSK Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 102. GSK Recent Developments
Table 103. Rakuten Medical Company Details
Table 104. Rakuten Medical Business Overview
Table 105. Rakuten Medical Antibody-drug Conjugate for Cancer Product
Table 106. Rakuten Medical Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024) & (US$ Million)
Table 107. Rakuten Medical Recent Developments
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 2. Global Antibody-drug Conjugate for Cancer Market Share by Type: 2023 VS 2030
Figure 3. Hematological Malignancies Drugs Features
Figure 4. Solid Tumor Drugs Features
Figure 5. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 6. Global Antibody-drug Conjugate for Cancer Market Share by Application: 2023 VS 2030
Figure 7. Hospital Case Studies
Figure 8. Pharmacy Case Studies
Figure 9. Other Case Studies
Figure 10. Antibody-drug Conjugate for Cancer Report Years Considered
Figure 11. Global Antibody-drug Conjugate for Cancer Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Antibody-drug Conjugate for Cancer Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Antibody-drug Conjugate for Cancer Market Share by Region: 2023 VS 2030
Figure 14. Global Antibody-drug Conjugate for Cancer Market Share by Players in 2023
Figure 15. Global Top Antibody-drug Conjugate for Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-drug Conjugate for Cancer as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Antibody-drug Conjugate for Cancer Revenue in 2023
Figure 17. North America Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
Figure 19. North America Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
Figure 20. North America Antibody-drug Conjugate for Cancer Market Share by Country (2019-2030)
Figure 21. United States Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Antibody-drug Conjugate for Cancer Market Size YoY (2019-2030) & (US$ Million)
Figure 24. Europe Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
Figure 25. Europe Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
Figure 26. Europe Antibody-drug Conjugate for Cancer Market Share by Country (2019-2030)
Figure 27. Germany Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. China Antibody-drug Conjugate for Cancer Market Size YoY (2019-2030) & (US$ Million)
Figure 34. China Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
Figure 35. China Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
Figure 36. Asia Antibody-drug Conjugate for Cancer Market Size YoY (2019-2030) & (US$ Million)
Figure 37. Asia Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
Figure 38. Asia Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
Figure 39. Asia Antibody-drug Conjugate for Cancer Market Share by Region (2019-2030)
Figure 40. Japan Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. South Korea Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. China Taiwan Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Southeast Asia Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. India Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Australia Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Size YoY (2019-2030) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Share by Type (2019-2030)
Figure 48. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Share by Application (2019-2030)
Figure 49. Middle East, Africa, and Latin America Antibody-drug Conjugate for Cancer Market Share by Country (2019-2030)
Figure 50. Brazil Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Mexico Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 52. Turkey Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. Israel Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 55. GCC Countries Antibody-drug Conjugate for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 56. Gilead Sciences Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 57. Roche Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 58. Pfizer Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 59. Takeda Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 60. Seagen Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 61. Innate Pharma Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 62. AstraZeneca Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 63. GSK Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 64. Rakuten Medical Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2019-2024)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Wireless Split Keyboard Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Global Ergonomic Adjustable Computer Chair Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Global Trackless Keyboard Tray Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232